LUTS pharmacotherapy: Any news?

Poster Session 69

  • Location:
    Room 14a (ICM, Level 1)
  • Chairs:
     A. Ergen, Ankara (TR)
     R. Umbas, Jakarta (ID)
     A. Sahai, London (GB)
  • Aims and objectives of this session

    Basic and clinical news from the wide field of LUTS pharmacotherapy will be covered during this session

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
Long term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: A randomized, prospective, comparative trial using a urodynamic study

By: Matsukawa Y., Takai S., Fujita T., Majima T., Kato M., Yamamoto T., Gotoh M.

Institutes: Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan

Dutasteride in combination with imidafenacin versus dutasteride alone for management of benign prostatic enlargement with overactive bladder: A multicenter, randomized controlled trial

By: Yamanishi T.1, Asakura H.2, Seki N.3, Tokunaga S.4

Institutes: 1Dokkyo Medical University, Dept. of Urology, Continence Center, Tochigi, Japan, 2Saitama Medical University Hospital, Dept. of Urology, Saitama, Japan, 3Kyushu Central Hospital, Dept. of Urology, Fukuoka, Japan, 4Kyushu University Hospital, Medical Information Center, Fukuoka, Japan

Effects of withdrawing the alpha-1 blocker from alpha-1 blocker plus 5-alpha-reductase inhibitor combination therapy on patients with benign prostatic hyperplasia from the perspective of urodynamic study

By: Matsukawa Y., Funahashi Y., Matsuo K., Ishida S., Yoshino Y., Yamamoto T., Gotoh M.

Institutes: Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan

Surgical outcome of BPH patients with storage symptoms requiring antimuscarinics before surgery – a nationwide population-based study

By: Huang E.Y-H., Chung H.J., Lin C-C., Fan Y.H., Peng R.S., Chang Y.H., Lin A.T.L., Chen K.K.

Institutes: Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan

Cardiovascular (CV) assessments in a randomized, double-blind, phase 3b trial of mirabegron add-on treatment in incontinent overactive bladder (OAB) patients with an inadequate response to solifenacin monotherapy

By: Drake M.J.1, Chapple C.2, Esen A.A.3, Athanasiou S.4, Cambronero J.5, Mitcheson D.6, Herschorn S.7, Huang M.8, Siddiqui E.8, Stozel M.9, Herholdt C.8, Mac Diarmid S.10

Institutes: 1University of Bristol, Bristol Urological Institute, Bristol, United Kingdom, 2Royal Hallamshire Hospital, Sheffield Hallam University, Sheffield, United Kingdom, 3Dokuz Eylül University School of Medicine, Dept. of Urology, Izmir, Turkey, 4University of Athens Medical School, Dept. of Urology, Athens, Greece, 5Hospital Universitario Infanta Leonor, Madrid, Spain, 6St Elizabeths Medical Center, Brighton, Massachusetts, United States of America, 7Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada, 8Astellas Pharma Europe Ltd, Chertsey, Surrey, United Kingdom, 9Astellas Pharma Global Development, Leiden, The Netherlands, 10Alliance Urology Specialists, Greensboro, North Carolina, United States of America

Tadalafil improves storage dysfunction via increase in bladder blood flow and suppression of ATP release from the urothelium in metabolic syndrome rats

By: Zha X., Ito H., Aoki Y., Matsuta Y., Yamaguchi H., Yokoyama O.

Institutes: Faculty of Medical Science, University Of Fukui, Dept. of Urology, Yoshida-gun, Japan

Alpha1-adrenoceptor antagonist ameliorates memory impairment in the patient with LUTS? A study about the influence of tamsulosin on the memory impairment through enhancement of alpha1A-adrenoceptor in the hippocampus of old-aged rats

By: Kim S.1, Kim CH2, Cho Y.S.3, Yoon S.J.2, Kim K.T.2, Kim T.B.2, Kim K.H.2

Institutes: 1The Catholic University of Korea, Kangnam St. Mary’s Hospital, Dept. of Urology, Seoul, South Korea, 2Gachon University Gil Medical Center, Gachon University School of Medicine, Dept. of Urology, Incheon, South Korea, 3Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea

Evaluation of tamsulosin therapy in the treatment of indwelling double–J stent related discomfort

By: Moussa A., Mohammed H., Abd-Bary A., Gaber A., El-Dessouky A., Masoud, A.

Institutes: Beni Suef University, Dept. of Urology, Beni Suef, Egypt

Role of silodosin in decreasing lower urinary tract and sexual problems in male patients with double J ureteral stents

By: Hussein H.A.1, Shaker H.2, Fathy H.1, Sheeba M.1, Abdelazim M.S.1, Bedair A.S.1, Aly A.H.1

Institutes: 1Cairo University, Dept. of Urology, Cairo, Egypt, 2Fayoum University, Dept. of Urology, Fayoum, Egypt

The efficacy and safety of onabotulinumtoxinA and solifenacin compared to placebo in solifenacin-naïve patients with idiopathic overactive bladder: Results from a multicentre, randomised, double-blind, phase 3b trial

By: Everaert K.1, Sriram R.2, Kohan A.3, Aliotta P.4, Mc Cammon K.5, Abrams S.6, Lam W.7, Herschorn S.8

Institutes: 1Ghent University Hospital, Dept. of Urology, Ghent, Belgium, 2University Hospital Coventry, Dept. of Urology, Coventry, United Kingdom, 3Advanced Urology Centers of New York, Dept. of Urology, Bethpage, United States of America, 4Western New York Urology Associates, Dept. of Urology, Williamsville, United States of America, 5Eastern Virginia Medical School, Dept. of Urology, Norfolk, United States of America, 6Allergan Plc, Dept. of Urology, Irvine, United States of America, 7Allergan Plc, Dept. of Biostatistics, Irvine, United States of America, 8University of Toronto, Dept. of Urology, Toronto, Canada

Licensed and approved vs traditional dose of onabotulinumtoxinA in refractory overactive bladder?

By: Eldred-Evans D.1, Seth J.1, Dowson C.2, Malde S.3, Watkins J.1, Khan M.S.1, Dasgupta P.1, Sahai A.1

Institutes: 1Guy’s and St Thomas’ Nhs Trust, Pelvic floor unit, London, United Kingdom, 2Guy’s and St Thomas’ Nhs Trust, Dept. of Urology, London, United Kingdom, 3University College London Hospitals NHS Foundation Trust, Dept. of Urology, London, United Kingdom

Preoperative serum C-reactive protein in patients with pelvic organ prolapse is a predictor of de novo overactive bladder

By: Tomohiro M., Ohba K., Yasuda T., Asai A., Miyata Y., Sakai H.

Institutes: Nagasaki University School of Medicine, Dept. of Urology, Nagasaki, Japan

Summary and context
 A. Sahai, London (GB)